The current studies extend these findings by demonstrating the humanized monoclonal antibody to CCR5, leronlimab, efficiently bound CCR5 expressed on human breast cancer cells, blocked ligand-induced Ca2+ signaling, and inhibited Matrigel invasion of breast cancer cells. This evidence concerns the gene CCR5 and breast cancer.